Core Insights - Two companies managed by AB Tewox have received construction permits for new grocery stores in Vilnius and Pabradė [1] - Both projects have secured long-term lease agreements with the supermarket chain Iki [1] Project Details - The grocery store in Vilnius will have a gross leasable area (GLA) of approximately 2,100 sqm, with a total investment projected at around EUR 6 million, and is planned to open in the second half of 2026 [1] - The grocery store in Pabradė will also have a GLA of approximately 2,100 sqm, with a total investment projected at around EUR 5 million, and is similarly planned to open in the second half of 2026 [1]

Group 1 - Orion Corporation has converted 182,827 A shares into B shares, with the conversion recorded on January 16, 2026 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,587,492 A shares and 109,546,786 B shares [1] - The total number of votes for the company's shares after the conversion is 741,296,626 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Core Viewpoint - Syensqo has published its financial calendar for 2026, inviting the financial community to take note of important dates related to earnings and shareholder meetings [1][7]. Financial Calendar Summary - Full year 2025 earnings will be reported on February 26, 2026 [2][8]. - The Ordinary Shareholders' Meeting is scheduled for May 5, 2026 [2][8]. - The First Quarter 2026 earnings will be announced on May 15, 2026 [2][8]. - The First Half Year 2026 earnings will be reported on July 30, 2026 [2][8]. - The First Nine Months 2026 earnings will be disclosed on November 5, 2026 [2][8]. - Quiet period dates will be communicated prior to each earnings season [2][8]. Company Overview - Syensqo is a science company focused on developing innovative solutions that enhance living, working, traveling, and leisure experiences [3][9]. - The company employs over 13,000 associates across 30 countries, inspired by the scientific councils initiated by Ernest Solvay in 1911 [3][9]. - Syensqo's solutions aim to create safer, cleaner, and more sustainable products across various sectors, including homes, food, consumer goods, aviation, automotive, batteries, smart devices, and healthcare [4][10].

Company Overview - VGP is a pan-European owner, manager, and developer of high-quality logistics and semi-industrial properties, as well as a provider of renewable energy solutions [3] - Founded in 1998 as a family-owned Belgian property developer in the Czech Republic, VGP now operates in 18 European countries with approximately 412 full-time employees [3] - As of June 2025, VGP's Gross Asset Value, including 100% joint ventures, was €8.3 billion, and the company had a Net Asset Value (EPRA NTA) of €2.6 billion [3] Tender Offer Details - The tender offer was announced on 8 January 2026, with a Final Acceptance Amount set at €100,000,000 [2] - The offer pertains to VGP's outstanding EUR 500,000,000 1.625% fixed-rate green bonds due 17 January 2027, of which €320,100,000 remained outstanding at the time of the offer launch [5] - The New Issue Condition has been satisfied, allowing bondholders to access further information through the tender results announcement available on VGP's website [2]

Core Viewpoint - Bigben Interactive is convening a meeting for bondholders to vote on amendments to the terms and conditions of its exchangeable bonds due in 2026, following a new bank financing of 43 million euros aimed at a partial redemption of these bonds [2][3][5]. Group 1: Financial Restructuring - The company announced a refinancing agreement of 43 million euros to facilitate a partial redemption of its exchangeable bonds [2][3]. - The outstanding amount of the bonds is currently 57.4 million euros, redeemable at maturity at 103% of their principal value, totaling 59.1 million euros [6]. - The proposed amendments include a partial redemption of 75,000 euros per bond, reducing the principal amount per bond from 100,000 euros to 28,000 euros [13]. Group 2: Proposed Amendments - The amendments will extend the maturity date of the non-redeemed portion of the bonds to August 19, 2032, which is a 6.5-year extension [9][15]. - The initial unit exchange price will be reduced to 0.85 euros until August 19, 2029, and then to 0.80 euros until maturity, compared to the initial price of 9.60 euros [9][15]. - The coupon rate will gradually increase from 1.125% to 5.125% over the life of the bonds [9][15]. Group 3: Bondholder Meeting - A general meeting of bondholders is scheduled for February 2, 2026, to vote on the proposed amendments, with 51% of bondholders already committed to voting in favor [2][7][20]. - If a quorum is not reached, a second meeting will be convened on February 13, 2026 [20]. - The agenda for the meeting includes the approval of the amendments and the filing of related documents [22].

Core Insights - Hydro's fourth quarter results for 2025 will be released on February 13, 2025, at 07:00 CET [1] - The integrated annual report for 2025 will be available the same day at 08:00 CET [1] Group 1 - President and CEO Eivind Kallevik and Executive Vice President and CFO Trond Olaf Christophersen will host a webinar in English at 08:30 CET on the same day [2] - A Q&A session will follow the presentation, and there will be no physical presentation or press conference [2] - The webinar can be accessed via a link to the webcast page, and no prior login or registration is required [2] Group 2 - Dial-in options are available for participants from Norway, the UK, and the US [2] - The meeting ID for the webinar is 920 8167 1402 [2] - Companies are advised to check for any restrictions on using the Zoom platform in advance [2] Group 3 - Investor contact for inquiries is Baard Erik Haugen, with provided contact details [3] - The information is subject to disclosure requirements under the Norwegian Securities Trading Act [3]

Group 1 - Sampo plc has conducted a share buyback on 15 January 2026, acquiring a total of 277,459 A shares at an average price of EUR 10.01 per share [1] - The share buyback program, announced on 5 November 2025, has a maximum limit of EUR 150 million and is in compliance with the Market Abuse Regulation [1] - The buyback program commenced on 6 November 2025, following authorization from Sampo's Annual General Meeting held on 23 April 2025 [1] Group 2 - After the recent transactions, Sampo plc now holds a total of 11,914,029 A shares, which represents 0.45% of the total number of shares in the company [2] - Detailed information regarding each transaction is available in the appendix of the announcement [2]

Core Viewpoint - BridgeBio Pharma, Inc. has announced the pricing of $550 million in 0.75% convertible senior notes due 2033, aimed at raising funds for various corporate purposes, including repurchasing existing convertible notes and shares [1][3][8]. Group 1: Offering Details - The offering consists of $550 million aggregate principal amount of 0.75% convertible senior notes, with an option for initial purchasers to buy an additional $82.5 million [1][2]. - The expected net proceeds from the sale are approximately $538.4 million, or $619.3 million if the option is fully exercised [2]. - The notes will bear interest at a rate of 0.75% per year, payable semi-annually, and will mature on February 1, 2033 [5][8]. Group 2: Use of Proceeds - The net proceeds will be used to repurchase or settle obligations related to the Company's 2.50% convertible senior notes due 2027 and for general corporate purposes [3]. - Approximately $82.5 million of cash on hand will be used to repurchase about 1.1 million shares of common stock from certain purchasers of the notes [4]. Group 3: Conversion and Redemption Terms - The initial conversion rate is set at 9.0435 shares per $1,000 principal amount of notes, equating to an initial conversion price of approximately $110.58 per share, representing a 45% premium over the last reported sale price of $76.26 [6][8]. - The Company may redeem the notes starting February 6, 2030, under certain conditions, at a redemption price equal to 100% of the principal amount plus accrued interest [7][10]. Group 4: Company Overview - BridgeBio Pharma is focused on developing transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [13].

Core Viewpoint - BW Energy reported preliminary operational figures for Q4 2025, indicating a decrease in production due to maintenance issues and lower sales volumes compared to previous quarters [2][3]. Production Summary - Net production for Q4 2025 was 2.3 million barrels of oil (mmbbls), averaging 25.2 thousand barrels of oil per day (kbopd) [2][4]. - For the full year 2025, net production totaled 10.9 mmbbls, equivalent to 29.9 kbopd, which is near the lower end of the guided range of 11-12 mmbbls [3][4]. Operational Costs - Net operational costs for the full year 2025 were reported at 20 USD per barrel, within the guided range of 19-21 USD per barrel [3]. Quarterly Comparison - Q4 2025 production decreased from 2.4 mmbbls in Q3 2025 and 3.1 mmbbls in Q4 2024 [4]. - Average realized price for Q4 2025 was 62.2 USD per barrel, down from 68.5 USD in Q3 2025 and 72.6 USD in Q4 2024 [4]. Inventory and Sales - End of quarter stock inventory was 0.9 mmbbls, an increase from 0.3 mmbbls in Q3 2025 [4]. - Net volume sold in Q4 2025 was 1.8 mmbbls, down from 2.9 mmbbls in Q3 2025 and 3.2 mmbbls in Q4 2024 [4]. Company Overview - BW Energy focuses on low-risk phased developments in proven offshore oil and gas reservoirs, with significant interests in various fields in Gabon and Brazil [7]. - The company holds a 73.5% interest in the Dussafu Marine license in Gabon and a 100% interest in the Golfinho field in Brazil, among other assets [7]. - Total net 2P+2C reserves and resources were 599 million barrels of oil equivalent at the start of 2025 [7].

Core Viewpoint - Perseus Mining Limited reports a tragic incident involving the fatal injury of an employee, Mr. Moussa Doumbia, in an offsite vehicle accident near the Bagoé Gold Mine in Côte d'Ivoire on January 15, 2026 [2][3]. Group 1 - The company expresses condolences to Mr. Doumbia's family and is providing support to them during this difficult time [3]. - Both Perseus and its ore haulage contractor, Binkadi, are offering assistance to their team at the Sissingué complex as they cope with the loss of a colleague [3]. - An investigation into the accident has been initiated by Perseus, in consultation with the relevant Ivorian authorities [3].